ARTICLE | Company News
Kadcyla sales and marketing update
January 6, 2017 8:38 PM UTC
The U.K.'s NICE issued draft guidance recommending against the use of Kadcyla trastuzumab emtansine from Roche’s Genentech unit to treat HER2-positive, locally advanced or metastatic breast cancer du...
BCIQ Target Profiles
Epidermal growth factor receptor 2 (HER2) (EGFR2) (ErbB2) (neu)